Psyence Biomedical (PBM) Financial Ratios

For fiscal 2026 (fiscal year ended Mar 31, 2026), Psyence Biomedical had return on equity of -58.6%, a current ratio of 14.62 (up from 11.04) and return on assets of -31.3% (up from -54.2%). A current ratio of 14.62 means current assets exceed current liabilities.

Psyence Biomedical Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period ending	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Valuation Ratios
P/E Ratio	-	2.69	-	-	-
P/B Ratio	0.33	0.40	-1.39	-485.22	192.34
Price/Tangible Book	0.33	0.40	-	-	192.34
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)	-58.62%	-	-	-468.63%	-
Return on Assets (ROA)	-31.33%	-54.20%	-126.35%	-123.25%	-
Return on Capital Employed (ROCE)	-36.80%	-54.50%	25.10%	1613.80%	-109.20%
Leverage & Solvency Ratios
Debt/Equity	-	-	-0.95	-	-
Liquidity Ratios
Current Ratio	14.62	11.04	0.09	0.89	13.90
Quick Ratio	12.12	10.55	0.06	0.83	13.62
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield	-122.95%	37.25%	-335.16%	-3.30%	-0.57%
FCF Yield	-144.34%	-137.84%	-19.33%	-1.64%	-0.43%
Buyback Yield	-1688.07%	-	-	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Psyence Biomedical Financial Ratios

What is Psyence Biomedical's return on equity?

Psyence Biomedical's return on equity (ROE) was -58.6% for fiscal 2026 (period ended Mar 31, 2026).

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition